fgf17 Antibody

What is FGF-17 and why is it significant in biological research?

FGF-17 is a member of the fibroblast growth factor family that plays critical roles in regulating cell growth, differentiation, and embryonic development. It is particularly important in the development of the central nervous system and limb structures. FGF-17 is predominantly located in the extracellular space where it interacts with fibroblast growth factor receptors (FGFRs) to initiate signaling cascades that promote cellular proliferation and survival. This extracellular localization enables FGF-17 to influence neighboring cells, impacting tissue development and repair processes. The precise regulation of FGF-17 expression during embryogenesis highlights its significance in organogenesis and complex structure formation. Additionally, aberrations in FGF-17 signaling pathways have been implicated in various neurological disorders, making it an important target for therapeutic research .

What types of FGF-17 antibodies are available for research purposes?

FGF-17 antibodies available for research include both monoclonal and polyclonal varieties, with mouse monoclonal antibodies being particularly common. For instance, the FGF-17 Antibody (B-4) is a mouse monoclonal IgG1 kappa light chain antibody that specifically detects FGF-17 protein from mouse, rat, and human origins. These antibodies are available in both non-conjugated forms and various conjugated forms to suit different experimental needs. Conjugated versions include those with agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. Each conjugation provides specific advantages for different detection methods and experimental designs, allowing researchers to select the most appropriate tool for their particular application .

How does FGF-17 function in normal physiological processes?

FGF-17 functions as a signaling molecule that binds to and activates FGF receptors, initiating downstream signaling cascades. In normal physiological processes, FGF-17 contributes to cellular proliferation, differentiation, and survival. Research has demonstrated that FGF-17 plays essential roles in embryonic development, particularly in the formation of the central nervous system and limb structures. Its expression is precisely regulated during embryogenesis to ensure proper organogenesis. FGF-17 signaling through the ERK1/2 pathway has been shown to increase cell proliferation, which is particularly evident in studies of mesenchymal stem cells under hypoxic conditions. Beyond its role in development, FGF-17 continues to influence tissue homeostasis and repair processes in adult organisms by mediating intercellular communication in the extracellular space .

What experimental techniques can be performed using FGF-17 antibodies?

FGF-17 antibodies can be utilized in numerous experimental techniques to detect, quantify, and visualize FGF-17 protein expression. Western blotting (WB) allows for protein size determination and semi-quantitative analysis of FGF-17 expression in tissue or cell lysates. Immunoprecipitation (IP) enables the isolation of FGF-17 protein complexes to study protein-protein interactions. Immunofluorescence (IF) provides visualization of FGF-17 localization within cells, revealing its spatial distribution. Immunohistochemistry with paraffin-embedded sections (IHCP) allows for detection of FGF-17 in preserved tissue samples, providing insights into its expression patterns in various tissues. Enzyme-linked immunosorbent assay (ELISA) offers quantitative measurement of FGF-17 concentrations in biological fluids or cell culture media. Each technique provides different information about FGF-17 expression, localization, or function, and selection depends on the specific research question being addressed .

How should experimental design be approached when studying FGF-17 under hypoxic conditions?

When designing experiments to study FGF-17 under hypoxic conditions, researchers should incorporate several critical considerations. First, establish appropriate hypoxic conditions (e.g., 1% O₂) with proper controls (normoxic conditions, typically 21% O₂). Cell culture media changes and passaging should be performed carefully, noting that these are typically conducted in normoxic environments even for hypoxic experiments. When studying hypoxia effects on FGF-17 expression, researchers should consider cell type-specific responses, as demonstrated in studies with human Wharton's Jelly-derived mesenchymal stem cells (hWJ-MSCs). Time-course experiments are essential, as significant differences in FGF-17 expression and cell proliferation may only become apparent at later passages (e.g., passages 7-10). For protein analysis, collect conditioned media after cells reach approximately 90% confluency and incubate in serum-free medium for standardized periods (e.g., 18 hours). Concentrate proteins using appropriate filtration methods (e.g., centrifugation at 5,000×g for 1 hour using filters with a molecular weight cutoff of 3,000 Dalton) before analysis by protein antibody arrays or ELISA .

What protocols are recommended for measuring FGF-17 secretion in cell culture supernatants?

For measuring FGF-17 secretion in cell culture supernatants, ELISA is the recommended approach. Begin by culturing cells to approximately 90% confluency in complete medium, then replace with serum-free medium for 18 hours to collect secreted proteins without interference from serum proteins. Harvest the conditioned medium and concentrate it using centrifugal filters with an appropriate molecular weight cutoff (e.g., 3,000 Dalton) at 5,000×g for 1 hour. For ELISA analysis, dilute the concentrated conditioned medium (e.g., 1:3 dilution) and add 100 μl to antibody-coated wells in a 96-well plate. Follow manufacturer's protocols for incubation times and temperatures (typically 2 hours at 37°C with anti-FGF-17 antibody). Proceed with biotin-antibody incubation (1 hour at 37°C), followed by HRP-avidin treatment (1 hour at 37°C). After adding TMB substrate and stop solution, measure optical density at 450 nm using a microplate spectrophotometer. Alternatively, broader protein screening can be performed using antibody arrays to detect FGF-17 alongside other secreted factors, allowing for comprehensive analysis of the secretome under different experimental conditions .

How does FGF-17 signaling interact with key developmental pathways in stem cell differentiation?

FGF-17 signaling interfaces with multiple developmental pathways during stem cell differentiation, with complex regulatory relationships that vary by cell type and microenvironment. Research with human Wharton's Jelly-derived mesenchymal stem cells (hWJ-MSCs) has revealed that FGF-17 influences the expression of key differentiation-related genes. Specifically, when normoxic hWJ-MSCs are treated with recombinant FGF-17 (rFGF-17), differentiation markers such as adiponectin (adipogenic), Runx2 (osteogenic), and chondroadherin (chondrogenic) are downregulated. Conversely, silencing FGF-17 with siRNA upregulates these differentiation markers. The relationship becomes more complex under hypoxic conditions, where alkaline phosphatase (ALP), Runx2, and chondroadherin are upregulated in hWJ-MSCs, an effect that can be reversed by FGF-17 knockdown. Intriguingly, only chondroadherin is upregulated when hypoxic hWJ-MSCs are treated with rFGF-17, suggesting context-dependent regulation. These findings indicate that FGF-17 may function as a stemness maintenance factor in some contexts while promoting specific lineage commitment in others, highlighting the importance of considering oxygen tension and other microenvironmental factors when investigating FGF-17's role in stem cell biology .

What are the molecular mechanisms through which FGF-17 regulates cell proliferation?

FGF-17 regulates cell proliferation primarily through activation of the extracellular signal-regulated kinase (ERK1/2) pathway, a critical cascade within the mitogen-activated protein kinase (MAPK) signaling system. When FGF-17 binds to its cognate fibroblast growth factor receptors (FGFRs) on the cell surface, it triggers receptor dimerization and autophosphorylation. This initiates a signaling cascade that activates the Ras-Raf-MEK-ERK pathway, ultimately leading to the phosphorylation of ERK1/2. Activated ERK1/2 translocates to the nucleus where it phosphorylates transcription factors that control genes involved in cell cycle progression and proliferation. Experimental evidence from studies with hWJ-MSCs demonstrates that knockdown of FGF-17 using siRNA decreases cell proliferation in both normoxic and hypoxic conditions, while treatment with recombinant FGF-17 protein enhances proliferation. The dose-dependent nature of this response has been observed, with concentrations between 250-1,000 ng/ml of recombinant FGF-17 showing proliferative effects after 48 hours of treatment. These findings establish FGF-17 as a potent mitogenic factor that operates through well-defined signal transduction pathways to promote cell division and population expansion .

What role does FGF-17 play in cellular responses to hypoxic conditions?

FGF-17 serves as a critical mediator in cellular adaptations to hypoxic conditions, particularly in stem cell populations. Research with human Wharton's Jelly-derived mesenchymal stem cells (hWJ-MSCs) has revealed that hypoxia (1% O₂) significantly increases FGF-17 secretion compared to normoxic conditions (21% O₂). Protein antibody array analysis of conditioned medium showed a remarkable 5-fold increase in FGF-17 expression in hypoxic hWJ-MSCs at passage 10. This elevated expression correlates with enhanced cell proliferation observed in hypoxic hWJ-MSCs from passages 7 to 10. The functional significance of this upregulation has been confirmed through both gain- and loss-of-function experiments. Notably, hypoxia-induced proliferation can be inhibited by FGF-17 knockdown using siRNA, while exogenous recombinant FGF-17 can partially recapitulate the proliferative advantage of hypoxic conditions even in normoxic cells. These findings suggest that FGF-17 upregulation represents an adaptive response that enables cells to maintain proliferative capacity under oxygen-limited conditions, potentially through ERK1/2 pathway activation. This mechanism may be particularly relevant in developmental contexts where hypoxic niches regulate stem cell behavior or in pathological conditions such as tumor microenvironments .

How can researchers address antibody cross-reactivity issues when studying FGF family members?

Addressing cross-reactivity issues when studying closely related FGF family members requires systematic validation approaches. First, researchers should select antibodies specifically validated for their target FGF (e.g., FGF-17 Antibody B-4) and review documentation regarding specificity testing. Prior to main experiments, perform Western blot analysis using recombinant proteins for multiple FGF family members to confirm specificity for FGF-17 over related proteins like FGF-8, FGF-18, and FGF-20, which share sequence homology. Include appropriate positive controls (tissues/cells known to express FGF-17) and negative controls (tissues/cells known not to express FGF-17) in all experiments. For immunohistochemistry or immunofluorescence applications, conduct peptide competition assays where pre-incubation of the antibody with excess recombinant FGF-17 should abolish specific staining. Additionally, employ parallel detection methods such as combining antibody-based techniques with mRNA analysis (RT-PCR or in situ hybridization) to confirm expression patterns. When interpreting results, carefully distinguish between specific and non-specific signals based on expected molecular weight, subcellular localization patterns, and consistency across multiple detection methods .

What considerations are important when analyzing FGF-17 expression data from different experimental techniques?

When analyzing FGF-17 expression data across different experimental techniques, researchers must consider technique-specific limitations and interpretation frameworks. Western blotting provides information about protein size and relative abundance but requires careful normalization to loading controls and may not detect low-level expression. Immunoprecipitation can enrich for FGF-17 but may introduce biases based on protein-protein interactions. Immunofluorescence and immunohistochemistry offer spatial information but are semi-quantitative and subject to fixation artifacts. ELISA provides quantitative measurement but lacks spatial context. For optimal analysis, triangulate findings using multiple techniques (e.g., verify Western blot results with ELISA quantification). When comparing expression levels between conditions (e.g., hypoxic versus normoxic), ensure equivalent cell densities, passage numbers, and collection protocols. For secreted FGF-17 analysis, standardize the conditioning time and normalization method (per cell number or total protein). Statistical analysis should employ appropriate tests (t-tests for simple comparisons, ANOVA for multiple conditions) with sufficient biological replicates (minimum n=3). Finally, contextual interpretation is essential—changes in FGF-17 expression should be considered alongside functional readouts (proliferation, differentiation) and related pathway components to develop comprehensive mechanistic understanding .

What are the best practices for optimizing FGF-17 antibody-based detection methods?

Optimizing FGF-17 antibody-based detection methods requires systematic protocol refinement across several parameters. For Western blotting, determine optimal protein loading (typically 20-50 μg total protein) and antibody concentration through titration experiments, typically starting with 1:1000 dilution of FGF-17 Antibody (B-4) and adjusting as needed. Test multiple blocking agents (e.g., BSA, non-fat milk) to minimize background while maximizing specific signal. For immunofluorescence and immunohistochemistry, optimize fixation methods (paraformaldehyde versus methanol) and antigen retrieval techniques (heat-induced versus enzyme-based) based on tissue type. When performing ELISA, generate standard curves using recombinant FGF-17 protein (250-1000 ng/ml range) and dilute samples appropriately to fall within the linear range of detection. For all techniques, incorporate appropriate positive controls (e.g., tissues known to express FGF-17) and negative controls (primary antibody omission, isotype controls). When troubleshooting high background, systematic adjustments to washing steps, blocking conditions, and secondary antibody concentrations are recommended. For challenging samples, signal amplification strategies (e.g., biotin-streptavidin systems, tyramide signal amplification) may enhance detection sensitivity. Finally, when comparing results across experiments, maintain consistency in antibody lots, incubation times, and detection systems to ensure reproducibility and reliability of findings .

How might FGF-17 signaling be targeted for therapeutic applications in neurological disorders?

Targeting FGF-17 signaling for therapeutic applications in neurological disorders represents a promising frontier, given its established roles in central nervous system development and potential involvement in pathological processes. Strategic approaches might include: developing small molecule inhibitors that specifically block FGF-17 binding to its receptors; creating neutralizing antibodies against FGF-17 to modulate its activity in vivo; utilizing gene therapy to either enhance or suppress FGF-17 expression in specific neural tissues; or designing peptide mimetics that compete with FGF-17 for receptor binding. Researchers must consider the context-specific effects of FGF-17, as its impact varies across brain regions and developmental stages. For instance, while FGF-17 promotes cell proliferation through ERK1/2 pathway activation, inappropriate stimulation could potentially contribute to aberrant cell growth in certain contexts. Target validation would require rigorous testing in relevant disease models, starting with in vitro neuronal cultures, progressing to organoids, and culminating in appropriate animal models of specific neurological conditions. Monitoring both on-target therapeutic effects and potential off-target consequences would be essential, particularly given FGF-17's roles across multiple tissue types .

What are the most promising directions for understanding FGF-17's role in stem cell maintenance and differentiation?

The most promising research directions for understanding FGF-17's role in stem cell biology encompass multiple innovative approaches. Single-cell transcriptomics combined with lineage tracing would provide unprecedented resolution of how FGF-17 signaling influences cell fate decisions in heterogeneous stem cell populations. CRISPR-Cas9 genome editing to create conditional FGF-17 knockout models would enable precise temporal control over FGF-17 expression during differentiation processes. Investigating the intersection between hypoxia-responsive elements and FGF-17 regulatory regions could explain the significant upregulation of FGF-17 under low oxygen conditions. Multi-omics approaches integrating transcriptomics, proteomics, and metabolomics would provide comprehensive understanding of how FGF-17 orchestrates cellular responses. In vitro differentiation assays using recombinant FGF-17 at precisely defined stages of lineage commitment could resolve the apparently contradictory effects observed in different contexts. Exploring potential direct interactions between FGF-17 and other signaling pathways (Wnt, Notch, TGF-β) would elucidate its position within broader developmental networks. Finally, specialized 3D culture systems mimicking tissue-specific niches would better recapitulate the physiological context in which FGF-17 operates during development and tissue homeostasis .

How does the secretion of FGF-17 compare across different stem cell populations and microenvironmental conditions?

Comparative analysis of FGF-17 secretion across diverse stem cell populations and microenvironmental conditions represents a critical research avenue with implications for both basic biology and therapeutic applications. Current evidence from human Wharton's Jelly-derived mesenchymal stem cells (hWJ-MSCs) demonstrates significant upregulation of FGF-17 secretion under hypoxic conditions (1% O₂), with approximately 5-fold higher levels compared to normoxic conditions (21% O₂). This pattern likely varies across different stem cell types based on their native niche oxygen tensions. Comprehensive investigation would require standardized collection and analysis protocols across multiple stem cell populations, including embryonic stem cells, induced pluripotent stem cells, neural stem cells, and tissue-specific progenitors. Beyond oxygen tension, other microenvironmental factors warranting systematic examination include: substrate stiffness and composition; growth factor combinations; three-dimensional versus two-dimensional culture systems; cell density and paracrine signaling; and inflammatory cytokine exposure. Analytical approaches should combine quantitative measurement techniques like ELISA with protein antibody arrays to position FGF-17 within broader secretome profiles. Additionally, researchers should investigate potential post-translational modifications of secreted FGF-17 that might influence its bioactivity across different contexts .